Targeting tuberculosis through a small focused library of 1, 2, 3-triazoles

Molecular Diversity

Volumn 15, Issue 4, 2011, Pages 1017-1024

  Labadie, Guillermo R ^a   De La Iglesia, Agustina ^b   Morbidoni, Héctor R ^b  

^a Universidad Nacional de Rosario   (Argentina)

^b UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Click chemistry; Triazoles; Tuberculosis

Indexed keywords

(1 BENZYL 1H 1,2,3 TRIAZOL 4 YL)METHANOL; 1 (2 ETHOXY 2 OXOETHYL) 1H 1,2,3 TRIAZOLE 4 CARBOXYLIC ACID; 1 BENZYL 1H 1,2,3 TRIAZOLE 4 CARBOXYLIC ACID; 1 BENZYL 4 PHENYL 1H 1,2,3 TRIAZOLE; 1,2,3 TRIAZOLE; 4 PHENYL 1 (3 PHENYLPROPYL) 1H 1,2,3 TRIAZOLE; [1 (3 PHENYLPROPYL) 1H 1,2,3 TRIAZOL 4 YL]METHANOL; BENZYL 4 OCTYL 1H 1,2,3 TRIAZOLE; BENZYL 4 PENTYL 1H 1,2,3 TRIAZOLE; BENZYL 4 PROYL 1H 1,2,3 TRIAZOLE; ECONAZOLE; ETHYL 2 (4 OCTYL 1H 1,2,3 TRIAZOL 1 YL)ACETATE; ETHYL 2 (4 PENTYL 1H 1,2,3 TRIAZOL 1 YL)ACETATE; ETHYL 2 (4 PHENYL 1H 1,2,3 TRIAZOL 1 YL)ACETATE; ETHYL 2 (4 PROPYL 1H 1,2,3 TRIAZOL 1 YL)ACETATE; ETHYL 2 [4 (HYDROXYMETHYL) 1H 1,2,3 TRIAZOL 1 YL]ACETATE; FLUCONAZOLE; METHYL 1 (3 PHENYLPROPYL) 1H 1,2,3 TRIAZOLE 4 CARBOXYLATE; METHYL 1 BENZYL 1H 1,2,3 TRIAZOLE 4 CARBOXYLATE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CLICK CHEMISTRY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; IC 50; INHIBITION KINETICS; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

CLICK CHEMISTRY; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; SMALL MOLECULE LIBRARIES; TRIAZOLES;

EID: 84855219978     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-011-9319-0     Document Type: Article

References (44)

1. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C (2003) Tuberculosis. Lancet 362:887-899. doi:10.1016/S0140-6736(03)14333-4 (Pubitemid 37130100)
2. WHO (1993) Tuberculosis on the increase. World Health Forum 14:1-94
3. Espinal MA (2003) The global situation of MDR-TB. Tuberculosis 83:44-51. doi:10.1016/S1472-9792(02)00058-6 (Pubitemid 36686747)
4. Afanas'ev M, Ikryannikova L, Il'ina E, Kuz'min A, Larionova E, Smirnova T, Chernousova L, Govorun V (2011) Molecular typing of Mycobacterium tuberculosis circulated in Moscow, Russian Federation. Eur J Clin Microbiol Infect Dis 30:181-191. doi:10.1007/s10096-010-1067-z
5. Coker R (2001) Detention and mandatory treatment for tuberculosis patients in Russia. Lancet 358:349-350. doi:10.1016/S0140-6736(01)05587-8 (Pubitemid 32739092)
6. World Health Organization (2002) Global tuberculosis control: surveillance, planning, financing. WHO/CDS/TB/2002.295.World Health Organization, Geneva, Switzerland
7. Sepkowitz K, Raffalli J, Riley L, Kiehn T, Armstrong D (1995) Tuberculosis in the AIDS era. ClinMicrobiol Rev 8:180-199
8. JaninYL (2007) Antituberculosis drugs: ten years of research.Bioorg Med Chem 15:2479-2513. doi:10.1016/j.bmc.2007.01.030 (Pubitemid 46367698)
9. Spalding MD, Prigge ST (2010) Lipoic acid metabolism in microbial pathogens.Microbiol Mol Biol Rev 74:200-228. doi:10.1128/MMBR.00008-10
10. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48:77-84. doi:10.1046/j.1365-2958.2003.03425.x (Pubitemid 36411469)
11. Ma Q, Zhao X, Nasser Eddine A, Geerlof A, Li X, Cronan JE, Kaufmann SH, Wilmanns M (2006) The Mycobacterium tuberculosis LipB enzyme functions as a cysteine/lysine dyad acyltransferase. Proc Natl Acad Sci USA 103:8662-8667. doi:10.1073/pnas.0510436103 (Pubitemid 43878077)
12. Morbidoni HR, Vilcheze C, Kremer L, Bittman R, Sacchettini JC, Jacobs WR Jr (2006) Dual inhibition of mycobacterial fatty acid biosynthesis and degradation by 2-alkynoic acids. Chem Biol 13:297-307. doi:10.1016/j.chembiol. 2006.01.005
13. Vilcheze C, Morbidoni HR, WeisbrodTR, IwamotoH, Kuo M, Sacchettini JC, JacobsWR Jr (2000) Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol 182:4059-4067. doi:10. 1128/JB.186.13.4051-4055.2004 (Pubitemid 30436569)
14. Lu H, Tonge PJ (2008) Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc Chem Res 41:11-20. doi:10.1021/ar700156e
15. Sullivan TJ, Truglio JJ, Boyne ME, Novichenok P, Zhang X, Stratton CF, Li HJ, Kaur T, Amin A, Johnson F, Slayden RA, Kisker C, Tonge PJ (2006) High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem Biol 1:43-53. doi:10.1021/cb0500042
16. Rivers EC, Mancera RL (2008) New anti-tuberculosis drugs with novel mechanisms of action. Curr Med Chem 15:1956-1967. doi:10.2174/092986708785132906
17. McLean KJ, MarshallKR, Richmond A, Hunter IS, FowlerK, Kieser T, Gurcha SS, Besra GS, Munro AW (2002) Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology 148:2937-2949 (Pubitemid 35243693)
18. Ahmad Z, Sharma S, Khuller GK (2005) In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett 251:19-22. doi:10.1016/j.femsle.2005.07.022 (Pubitemid 41306223)
19. Ahmad Z, Sharma S, Khuller GK (2006) The potential of azole antifungals against latent/persistent tuberculosis. FEMSMicrobiol Lett 258:200-203. doi:10.1111/j.1574-6968.2006.00224.x
20. Ahmad Z, Sharma S, Khuller GK (2006) Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett 261:181-186. doi:10.1111/j.1574-6968.2006.00350.x (Pubitemid 44134150)
21. Jadhav GR, Shaikh MU, Kale RP, Shiradkar MR, Gill CH (2009) SARstudy of clubbed [1, 2, 4]-triazolylwith fluorobenzimidazoles as antimicrobial and antituberculosis agents. Eur JMed Chem 44:2930-2935. doi:10.1016/j.ejmech.2008. 12.001
22. Ozdemir A, Turan-Zitouni G, Kaplancikli ZA, Chevallet P (2007) Synthesis of some 4-arylidenamino-4H-1, 2, 4-triazole-3- thiols and their antituberculosis activity. JEnzyme InhibMedChem 22:511-516. doi:10.1080/14756360601178424 (Pubitemid 47225716)
23. Kaplancikli ZA, Turan-Zitouni G, Chevallet P (2005) Synthesis and antituberculosis activity of new 3-alkylsulfanyl-1, 2, 4-triazole derivatives. J Enzyme Inhib Med Chem 20:179-182. doi:10.1080/14756360500043471 (Pubitemid 40645507)
24. Shiradkar MR, Murahari KK, Gangadasu HR, Suresh T, Kalyan CA, Panchal D, Kaur R, Burange P, Ghogare J, Mokale V, Raut M (2007) Synthesis of new S-derivatives of clubbed triazolyl thiazole as anti-Mycobacterium tuberculosis agents. BioorgMedChem 15:3997-4008. doi:10.1016/j.bmc.2007.04.003 (Pubitemid 46695827)
25. Dabak K, Sezer O, Akar A, Anac O (2003) Synthesis and investigation of tuberculosis inhibition activities of some 1, 2, 3-triazole derivatives. Eur J Med Chem 38:215-218. doi:10.1016/S0223-5234(02)01445-9 (Pubitemid 36288475)
26. Costa MS, Boechat N, Rangel EA, de C. da Silva F, de Souza AM, Rodrigues CR, Castro HC, Junior IN, Lourenco MC, Wardell SM, Ferreira VF (2006) Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1, 2, 3-triazole derivatives. BioorgMed Chem 14:8644-8653. doi:10.1016/j.bmc.2006.08. 019 (Pubitemid 44679826)
27. Gill C, Jadhav G, Shaikh M, Kale R, Ghawalkar A, Nagargoje D, Shiradkar M (2008) Clubbed [1, 2, 3] triazoles by fluorine benzimidazole: a novel approach to H37Rv inhibitors as a potential treatment for tuberculosis. Bioorg Med Chem Lett 18:6244-6247. doi:10.1016/j.bmcl.2008.09.096
28. Kolb HC, Sharpless KB (2003) The growing impact of click chemistry on drug discovery. Drug Discov Today 8:1128-1137. doi:10.1016/S1359-6446(03)02933-7 (Pubitemid 37547919)
29. Tron GC, Pirali T, Billington RA, Canonico PL, Sorba G, Genazzani AA (2008) Click chemistry reactions in medicinal chemistry: applications of the 1, 3-dipolar cycloaddition between azides and alkynes. Med Res Rev 28:278-308. doi:10.1002/med.20107 (Pubitemid 351281190)
30. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB (2002) A stepwise Hüisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem Int Ed Engl 41:2596-2599. doi:10.1002/1521-3773(20020715)41:14 (Pubitemid 34803480)
31. Lee B-Y, Park SR, JeonHB, KimKS (2006) Anewsolvent system for efficient synthesis of 1, 2, 3-triazoles. Tetrahedron Lett 47:5105-5109. doi:10.1016/j.tetlet.2006.05.079 (Pubitemid 43867620)
32. Angelo NG, Arora PS (2007) Solution- and solid-phase synthesis of triazole oligomers that display protein-like functionality. J Org Chem 72:7963-7967. doi:10.1021/jo701292h (Pubitemid 47582582)
33. VijayaRaghava Reddy L, Venkat Reddy P, Mishra NN, Shukla PK, Yadav G, Srivastava R, Shaw AK (2010) Synthesis and biological evaluation of glycal-derived novel tetrahydrofuran 1, 2, 3-triazoles by 'click' chemistry. Carbohydr Res 345:1515-1521. doi:10.1016/j.carres.2010.03.031
34. Jlalia I, Beauvineau C, Beauvière S, ÖnenE, AufortM, Beauvineau A, KhabaE, Herscovici J, Meganem F, GirardC (2010) Automated synthesis of a 96 product-sized library of triazole derivatives using a solid phase supported copper catalyst. Molecules 15:3087-3120. doi:10.3390/ molecules15053087
35. Turner RA, OliverAG, Lokey RS (2007) Click chemistry as amacrocyclization tool in the solid-phase synthesis of small cyclic peptides. Org Lett 9:5011-5014. doi:10.1021/ol702228u
36. Colombano G, Travelli C, Galli U, Caldarelli A, Chini MG, Canonico PL, Sorba G, Bifulco G, Tron GC, Genazzani AA (2009) A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry. J Med Chem 53:616-623. doi:10.1021/jm9010669
37. Jia Z, Zhu Q (2010) 'Click' assembly of selective inhibitors for MAO-A. Bioorg Med Chem Lett 20:6222-6225. doi:10.1016/j.bmcl.2010.08.104
38. Choi KW, Brimble MA (2008) Synthesis of spiroacetal-triazoles as privileged natural product-like scaffolds using "click chemistry". Org Biomol Chem 6:3518-3526. doi:10.1039/b808454h
39. Bagwell CL, Moloney MG, Yaqoob M (2010) Oxazolomycins: natural product lead structures for novel antibacterials by click fragment conjugation. Bioorg Med Chem Lett 20:2090-2094. doi:10. 1016/j.bmcl.2010.02.066
40. Philalay JS, Palermo CO, Hauge KA, Rustad TR, Cangelosi GA (2004) Genes required for intrinsic multidrug resistance in Mycobacterium avium. Antimicrob Agents Chemother 48:3412-3418. doi:10.1128/AAC.48.9.3412-3418.2004 (Pubitemid 39129339)
41. Barry CEIII, Slayden RA, Sampson AE, Lee RE (2000) Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem Pharmacol 59:221-231. doi:10. 1016/S0006-2952(99)00253-1 (Pubitemid 30001748)
42. Prado S, Ledeit H, Michel S, Koch M, Darbord JC, Cole ST, Tillequin F, Brodin P (2006) Benzofuro[3, 2-f][1]benzopyrans: a new class of antitubercular agents. Bioorg Med Chem 14:5423-5428. doi:10.1016/j.bmc.2006.03.033 (Pubitemid 43903242)
43. Appukkuttan P, Dehaen W, Fokin VV, Van der Eycken E (2004) A microwave-assisted click chemistry synthesis of 1, 4-disubstituted 1, 2, 3-triazoles via a copper(I)-catalyzed three-component reaction. Org Lett 6:4223-4225. doi:10.1021/ol048341v (Pubitemid 39563449)
44. Babich H, Borenfreund E (1991) Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay. Appl Environ Microbiol 57:2101-2103